Invitation to submit Phase II contract, Glyco Scientific 75N93023C00038
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is inviting Glyco Scientific to submit a Phase II contract proposal under forecast 75N93023C00038, a new requirement with an estimated solicitation release date of 2026-10-01 and an estimated award date of 2027-06-01. The Phase II effort expands Glyco Scientific's Phase I work, which generated and validated reagents for unique immune models used to study Mycobacterium tuberculosis, into producing additional reagents for biomedical research on health and disease.
The estimated award value range is $1.5 million to $3.0 million, and the forecast is a total small business set-aside under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Contracting Officer Callie Prassinos (callie.prassinos@nih.gov, +1 240-669-5155) and Stacy Ferguson of the National Institute of Allergy and Infectious Diseases (fergusonst@niaid.nih.gov) are the listed points of contact.
Forecast text
This PCAIS entry is to request that Glyco Scientific be invited to submit a Phase II contract proposal. This contractor provided significant benefit to the government in their prior Phase I contract by successfully generating and validating reagents needed for unique immune models for the study of Mycobacterium tuberculosis, the causitive agent of TB disease. The Phase II invitation will be an expansion of these activities including generation of more unique reagents needed in the biomedical field for studying health and disease.
Statement of impact: If this PCAIS entry is not approved, this will reduce the ability of the government to invest in the generation of reagents that are needed to conduct research using unique immune models that are important for studying health and disease, by not allowing a contractor with the capacity to generate the reagents the opportunity to submit a contract proposal for consideration.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast